CL2016002255A1 - Inhibidores de c5a para el tratamiento de la neumonía viral - Google Patents

Inhibidores de c5a para el tratamiento de la neumonía viral

Info

Publication number
CL2016002255A1
CL2016002255A1 CL2016002255A CL2016002255A CL2016002255A1 CL 2016002255 A1 CL2016002255 A1 CL 2016002255A1 CL 2016002255 A CL2016002255 A CL 2016002255A CL 2016002255 A CL2016002255 A CL 2016002255A CL 2016002255 A1 CL2016002255 A1 CL 2016002255A1
Authority
CL
Chile
Prior art keywords
inhibitors
treatment
viral pneumonia
pneumonia
viral
Prior art date
Application number
CL2016002255A
Other languages
English (en)
Inventor
Renfeng Guo
Niels Christoph Riedemann
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50342223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002255(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of CL2016002255A1 publication Critical patent/CL2016002255A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2016002255A 2014-03-20 2016-09-06 Inhibidores de c5a para el tratamiento de la neumonía viral CL2016002255A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14160947 2014-03-20

Publications (1)

Publication Number Publication Date
CL2016002255A1 true CL2016002255A1 (es) 2017-08-25

Family

ID=50342223

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002255A CL2016002255A1 (es) 2014-03-20 2016-09-06 Inhibidores de c5a para el tratamiento de la neumonía viral

Country Status (15)

Country Link
US (2) US10227397B2 (es)
EP (1) EP3119802B1 (es)
JP (2) JP6718379B2 (es)
KR (1) KR20160127042A (es)
CN (2) CN106132982A (es)
AU (1) AU2015233380A1 (es)
BR (1) BR112016021629A2 (es)
CA (1) CA2940319A1 (es)
CL (1) CL2016002255A1 (es)
EA (1) EA201691481A1 (es)
IL (1) IL247364A0 (es)
MX (1) MX2016011862A (es)
PH (1) PH12016501830A1 (es)
SG (1) SG11201607740TA (es)
WO (1) WO2015140304A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535890A (zh) 2014-03-20 2017-03-22 萨穆梅德有限公司 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
CA2940319A1 (en) 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
US20190127453A1 (en) 2016-06-07 2019-05-02 Novartis Ag An anti-c5 antibody dosing regimen
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
TWI826364B (zh) * 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
TWI786132B (zh) * 2017-06-23 2022-12-11 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療
WO2021034639A1 (en) 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. High concentration anti-c5 formulations
TWI834025B (zh) * 2020-03-06 2024-03-01 美商奥默羅斯公司 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
PH12022552556A1 (en) 2020-03-27 2024-04-22 Inflarx Gmbh Inhibitors of c5a for the treatment of corona virus infection
EP4135837A1 (en) * 2020-04-16 2023-02-22 Assistance Publique, Hopitaux De Paris Methods for treating a complement mediated disorder caused by viruses
TW202208427A (zh) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
US20240415980A1 (en) 2021-10-28 2024-12-19 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283594T5 (es) * 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
US8071096B2 (en) * 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
JP5840623B2 (ja) * 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
KR101849738B1 (ko) * 2010-06-17 2018-04-17 트렐리스 바이오싸이언스 인코포레이티드 수동 인플루엔자 면역에 유용한 항체
CA2940319A1 (en) 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia

Also Published As

Publication number Publication date
US20170137499A1 (en) 2017-05-18
JP6718379B2 (ja) 2020-07-08
US10227397B2 (en) 2019-03-12
AU2015233380A1 (en) 2016-09-08
KR20160127042A (ko) 2016-11-02
WO2015140304A1 (en) 2015-09-24
IL247364A0 (en) 2016-11-30
CN116785426A (zh) 2023-09-22
CN106132982A (zh) 2016-11-16
SG11201607740TA (en) 2016-10-28
PH12016501830A1 (en) 2016-11-21
US20190202900A1 (en) 2019-07-04
BR112016021629A2 (pt) 2018-07-10
EP3119802A1 (en) 2017-01-25
EP3119802B1 (en) 2019-12-04
US10858421B2 (en) 2020-12-08
EA201691481A1 (ru) 2017-02-28
CA2940319A1 (en) 2015-09-24
MX2016011862A (es) 2016-12-05
JP2020125324A (ja) 2020-08-20
JP7041708B2 (ja) 2022-03-24
JP2017514791A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
CL2016002255A1 (es) Inhibidores de c5a para el tratamiento de la neumonía viral
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
DK3132036T3 (da) Målrettede mutationer
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
IL248661A0 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
BR112016021682A2 (pt) cenicriviroc para o tratamento da fibrose
PL3166834T3 (pl) Układy stacji napędowych
SG11201609652RA (en) Treatment of polybacterials infections
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3132009T3 (da) Fremgangsmåde
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3283210T3 (da) Fremgangsmåde
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
LT3212237T (lt) Metotreksato vaistinė forma
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
FR3023290B1 (fr) Derives de flavaglines
HUE042043T2 (hu) Malária megelõzésére vagy kezelésére alkalmas triaminopiridin-vegyületek
IL254502B (en) Solid forms of menaquinols
GB201404552D0 (en) Purification of dna-conjugate products
IL248608A0 (en) Heparan sulphates
DK3205661T3 (da) Hsp70-afledt immunitetsinducerende peptid
FR3024647B1 (fr) Transat de puericulture
EP3217965C0 (en) Pharmaceutical processing
IL247553B (en) Transportation of medical instruments
DK3285588T3 (da) Fremgangsmåde